U.S., Dec. 17 -- ClinicalTrials.gov registry received information related to the study (NCT07283848) titled 'Zimberelimab + Domvanalimab in Gastroesophageal Adenocarcinoma' on Dec. 06.
Brief Summary: The purpose of the study is to understand whether study drugs domvanalimab and zimberelimab are safe and effective in combination with standard chemotherapy for patients with operable cancer of the esophagus, stomach, or gastroesophageal junction (where the stomach meets the esophagus).
All participants will receive the study treatment. Participants will receive chemotherapy and two immune therapies drugs (domvanalimab and zimberelimab) for up to 4 months before surgery. After surgery and at least a 4 week recovery, participants will receive ...